Berzosertib
- Generic Name
- Berzosertib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25N5O3S
- CAS Number
- 1232416-25-9
- Unique Ingredient Identifier
- L423PRV3V3
- Background
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
M6620 First in Human Study
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2020-04-01
- Target Recruit Count
- 200
- Registration Number
- NCT02157792
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Long Island Jewish Medical Center - Monter Cancer Center, Lake Success, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath